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Abstract
AIM: To investigate patient-reported outcomes from, 
and adherence to, a low FODMAP diet among patients 
suffering from irritable bowel syndrome and inflammatory 
bowel disease.
METHODS: Consecutive patients with irritable bowel 
syndrome (IBS) or inflammatory bowel disease (IBD) 
and co-existing IBS fulfilling the ROME Ⅲ criteria, 
who previously attended an outpatient clinic for 
low FODMAP diet (LFD) dietary management and 
assessment by a gastroenterologist, were invited to 
participate in a retrospective questionnaire analysis. 
The questionnaires were sent and returned by regular 
mail and gathered information on recall of dietary 
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INTRODUCTION
Irritable bowel syndrome (IBS) is a highly prevalent 
functional gastrointestinal disorder characterised by 
abdominal pain or discomfort in association with altered 
bowel habits and no organic disease. IBS symptoms 
are prevalent in about 10%-20% of the general 
population, with a female gender predilection and a 
high proportion of undiagnosed sufferers, making IBS a 
major health issue[1-3]. Furthermore, IBS-like symptoms 
are common in patients with inflammatory bowel 
disease (IBD) and are present in between 30%-40% of 
patients in clinical remission[4-6].
Treatment of IBS is a challenging task for primary 
care physicians and gastroenterologists due to the 
heterogeneity of the disorder, a lack of reliable outcome 
measures, and high placebo response rates. In the last 
decades, a diet excluding foods high in short-chained 
carbohydrates, termed FODMAPs (fermentable oligo-, 
di-, and monosaccharides and polyols), has proven 
effective in the treatment of functional gastrointestinal 
symptoms[7]. FODMAPs are poorly absorbed in the 
small intestine and are passed on to the colon, where 
they exert an osmotic effect, drawing fluid into the 
lumen and, furthermore, causing an increase in gas 
production (mainly hydrogen and methane) due to 
the excess delivery of fermentable substrates to the 
colonic microflora[8]. These mechanisms can lead to 
abdominal pain, bloating, flatulence, and diarrhoea 
in susceptible subjects[9,10]. There is strong evidence 
supporting the low FODMAP diet (LFD) as an effective 
therapeutic tool in the management of IBS with an 
overall response rate of 75[7,9,11-13]. The diet also seems 
to reduce functional bowel symptoms in patients with 
inflammatory bowel disease[14,15] and patients without 
a colon[8].
Adherence to the diet is key to its success and 
according to previous studies, adherence can be 
expected in up to 75% of patients[12,14,16]. However, 
many struggle with implementing the LFD in daily life 
due to its complexity. Currently, studies of long-term 
efficacy of the LFD are lacking, and no one has yet 
investigated the dietary impact on IBS disease course.
The present retrospective study aimed to examine 
patient-reported long-term effects of the LFD, dietary 
adherence, and dietary impact on disease course 
in patients with IBS and patients with IBD and co-
existing IBS.
MATERIALS AND METHODS
Study design
A retrospective, cross-sectional study was conducted 
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treatment, efficacy, symptoms, adherence, satisfaction, 
change in disease course and stool type, and quality of 
life. Before study enrolment all patients had to sign an 
informed written consent.
RESULTS: One hundred and eighty patients were 
included, 131 (73%) IBS and 49 (27%) IBD patients. 
Median age was 43 years (range: 18-85) and 147 (82%) 
were females. Median follow-up time was 16 mo (range: 
2-80). Eighty-six percent reported either partial (54%) 
or full (32%) efficacy with greatest improvement 
of bloating (82%) and abdominal pain (71%). The 
proportion of patients with full efficacy tended to be 
greater in the IBD group than in the IBS group (42% 
vs  29%, P  = 0.08). There was a significant reduction 
in patients with a chronic continuous disease course in 
both the IBS group (25%, P  < 0.001) and IBD group 
(23%, P  = 0.002) along with a significant increase in 
patients with a mild indolent disease course of 37% 
(P  < 0.001) and 23% (P  = 0.002), respectively. The 
proportion of patients having normal stools increased 
with 41% in the IBS group (P  < 0.001) and 66% 
in the IBD group (P  < 0.001). One-third of patients 
adhered to the diet and high adherence was associated 
with longer duration of dietary course (P  < 0.001). 
Satisfaction with dietary management was seen in 83 
(70%) IBS patients and 24 (55%) IBD patients. Eighty-
four percent of patients lived on a modified LFD, where 
some foods rich in FODMAPs were reintroduced, and 
16% followed the LFD by the book without deviations. 
Wheat, dairy products, and onions were the foods most 
often not reintroduced by patients.
CONCLUSION: These data suggest that a diet low in 
FODMAPs is an efficacious treatment solution in the 
management of functional bowel symptoms for IBS and 
IBD patients.
Key words: Low FODMAP; Irritable bowel syndrome; 
Inflammatory bowel disease; Adherence; Disease course
© The Author(s) 2016. Published by Baishideng Publishing 
Group Inc. All rights reserved.
Core tip: This is a retrospective study based on patient-
reported questionnaires to evaluate the low FODMAP 
diet (LFD) dietary course of patients with irritable bowel 
syndrome (IBS) or inflammatory bowel disease (IBD). 
Effect was reported by 86% of patients with greatest 
relief of abdominal pain and bloating. Long-term IBS 
disease course and stool type improved significantly 
after dietary intervention. One-third of patients were 
adherent and the majority was satisfied with the 
treatment. These are the first data on changes of long-
term IBS disease course following LFD treatment and 
the longest FU to date of IBS and IBD patients treated 
with the LFD with a median FU of 16 mo.
Maagaard L, Ankersen DV, Végh Z, Burisch J, Jensen L, 
Pedersen N, Munkholm P. Follow-up of patients with functional 
bowel symptoms treated with a low FODMAP diet. World J 
to investigate long-term adherence and effect on 
disease course in IBS and IBD patients treated with 
the LFD.
Study population
Consecutive patients with IBS or IBD and co-existing 
IBS fulfilling the Rome Ⅲ criteria[17] for IBS and having 
received LFD education followed by a dietary course of 
varying duration in the period 2009-2013, were invited 
to participate in the study. All patients had initially been 
treated by their general practitioner and subsequently 
been referred to Herlev University Hospital (HUH) for 
dietary management of IBS with clinical dieticians.
All study participants, or their legal guardian, provided 
informed written consent prior to study enrolment. 
Participants gave written informed consent for data 
sharing.
Prior to dietary consultation, gastroenterologists 
had assessed all patients and the majority of patients 
presented normal colonoscopy results, and were tested 
for lactose intolerance and celiac disease, among other 
relevant tests. 
Patients were excluded from the study if they 
had significant gastrointestinal co-morbidities such 
as abdominal cancer or ileo-/colostomy. IBD patients 
were not tested for level of disease activity at follow-
up.
eHealth: a web-program for IBS and IBD patients
Some of the recruited patients (103, 57%) had earlier 
been engaged in other LFD studies at HUH involving 
eHealth web-program monitoring and a dietary course 
of six weeks with follow-up evaluation[15,17,18]. The 
program has been described in previous papers[19]. 
The majority of IBD patients (40, 82%) included here 
participated in these eHealth studies, while patients 
with moderate to severe disease activity (assessed by 
HBI or SCCAI) were excluded.
Data collection
Patients eligible for the study received a letter con-
taining an invitation, an informed consent form, and 
a questionnaire regarding the dietary treatment, 
adherence to diet, disease severity and course, stool 
pattern, and quality of life. If the patients did not reply 
to the invitation, reminders were sent by regular mail. 
Before accessing electronic patient files for extraction 
of additional demographic data, an informed written 
consent for data sharing had to be signed by the 
patients in accordance with the Danish health authority 
regulations.
Dietary advice
Four experts in clinical nutrition and the LFD performed 
the dietary consultations. One dietician was FODMAP-
certified at King’s College, London, United Kingdom[20]. 
The initial consultation lasted 60-90 min and included 
IBS education, dietary history, LFD education, and 
individualisation of LFD advice in order to facilitate 
implementation of the diet. Patients were to stay on 
the diet for 6-8 wk and then review the treatment 
response with support from the dietary expert. If 
the response was considered satisfactory, patients 
continued the restriction of FODMAPs, but with reintro-
duction of small amounts of foods high in FODMAPs 
in order to determine individual tolerance level and 
ensure variety in diet. The patients were offered follow-
up consultations either in clinic or by telephone and 
were also able to email the experts.
Questionnaires
At follow-up, all patients were asked to complete a 
questionnaire analysis including four self-developed 
questionnaires and three or four internationally validated 
questionnaires.
The first questionnaire, developed in cooperation 
with clinical dieticians, consisted of 23 questions with 
limited answering options or visual analogue scales 
(VAS) addressing efficacy of diet, dietary mana-
gement, and compliance. The FODMAP Adherence 
Report Scale (FARS) was constructed to evaluate 
dietary adherence and was inspired by the validated 
Medication Adherence Report Scale by Byrne et al[21]. 
The scale consists of five questions (see Table 1), each 
question offering five possible answers (always, often, 
sometimes, rare, and never) scoring from one to five 
points with a maximum score of 25 points. A total 
score of at least 20 points (≥ 80%) was considered as 
adherence to the diet. Furthermore, a questionnaire 
previously applied in a study by Pedersen et al[17] 
at HUH was included in order to assess satisfaction 
with the dietary treatment. Its six questions were 
accompanied by VAS scales, with a scoring range of 
0-100 points (i.e., 1 cm = 10 points), and covered 
the following items: dietary consultations, distributed 
written material, flavour of diet, compliance/adherence 
to diet, and availability of appropriate foods in 
supermarkets. The maximum score was 600 points 
and a total score of a minimum of 360 points (≥ 
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Table 1  Dietary adherence at follow-up, estimated by the 
FODMAP adherence report scale  n  (%)
FARS questions All patients IBD IBS
“I change the content of a LFD meal 
despite the recommended content”
57 (35) 12 (28) 45 (37)
“I follow a modified LFD compared to 
the recommended LFD”
61 (37) 15 (34) 46 (38)
“I replace a LFD meal with a regular 
meal containing FODMAPs”
90 (55) 27 (63) 63 (53)
“I forget to follow the LFD” 111 (68) 33 (75) 78 (65)
“I stop taking the LFD for a period of time” 107 (65) 34 (77) 73 (61)
Each of the FARS questions had five possible responses, scoring 1-5 points. 
A score of ≥ 4 points was regarded as adherence to the LFD. FARS: 
FODMAP adherence report scale; IBD: Inflammatory bowel disease; 
IBS: Irritable bowel syndrome; LFD: Low FODMAP diet; FODMAPs: 
Fermentable oligo-, di- and monosaccharides and polyols.
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points, and above 300 points the disease is severe. 
Quality of life was evaluated at follow-up using the IBS 
Quality of Life questionnaire (IBS-QoL)[27] that contains 
34 questions, each with five possible answers and a 
scoring range of 34-170 points. Due to the absence of 
an official cut-off for good quality of life, we arbitrarily 
set the bar at ≤ 102 points (50%).
Finally, the Short IBD Questionnaire (SIBDQ)[28] is 
composed of 10 questions and was used to measure 
quality of life at follow-up for IBD patients only. A total 
score of 50 points or more was considered to indicate 
a good quality of life[29].
Statistical analysis
Statistical analysis was performed using the SAS v. 9.3 
(NC, United States) and SPSS v. 20 (IL, United States) 
statistical software packages. Standard descriptive 
statistics were carried out including frequency 
distributions for categorical data and calculation of 
medians and ranges for continuous variables. Fisher’s 
exact and χ 2 tests were used to investigate whether or 
not the differences in descriptive data between groups 
were significant. The Wilcoxon ranked test was applied 
to determine if there had been significant changes in 
disease course and stool type from baseline to follow-
60%) was considered as satisfaction with the dietary 
treatment.
The last questionnaire developed addressed changes 
in IBS disease course prior to, and after, dietary 
intervention and consisted of four figures depicting 
different types of disease courses, the Copenhagen 
IBS disease courses (see Figure 1). The figures 
were constructed based on several years of clinical 
experience in IBS management and studies of pattern 
recognition of IBD disease courses[22,23]. The mild 
indolent disease course was considered the preferred 
type, as disease activity decreased over time. The 
patients had to choose one figure representing their 
disease course before and after dietary management. 
The Bristol Stool Chart (BSC)[24,25] illustrates seven 
different stool types representing constipation (type 
1-2), normal stools (type 3-4), and diarrhoea (type 
5-7), and was used retrospectively to assess stool 
type prior to and after dietary treatment. The IBS 
Severity Scoring System (IBS-SSS)[26] was applied to 
measure IBS disease severity at follow-up and consists 
of five questions combined with VAS-scales, with the 
maximum score being 500 points. Remission/mild 
disease is classified as a score less than 175 points, 
moderate disease as a score between 175 and 300 
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Figure 1  Copenhagen irritable bowel syndrome disease courses. The four figures each depict a different type of IBS disease course with varying disease activity 
over time. The time span is from introduction of the LFD until follow-up. The same figures were used from time of diagnosis to introduction of the LFD (not shown). A: 
Mild IBS with indolent course: The disease activity fades over time; B: Mild IBS with aggressive course: The disease activity increases over time; C: Chronic IBS with 
continuous course: There is constant disease activity without remission periods; D: Chronic IBS with intermittent course: The disease activity appears in relapses with 
remission periods in between. LFD: Low FODMAP diet; IBS: Irritable bowel syndrome.
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up. Fisher’s exact test and multiple logistic regression 
were performed to examine the relationship between 
responses and explanatory variables. All reported 
P-values are two-sided and tests were performed with 
a 5% level of significance. The statistical methods of 
this study were reviewed by Henrik Wachmann, Larix 
A/S.
RESULTS
Demographic data
Four hundred and three (294 IBS, 109 IBD) patients 
eligible for the study were identified. Fifteen were 
excluded due to co-morbidity (eight), migration (four), 
or uncertain IBS diagnosis (three). Forty patients 
rejected the invitation. Of the remaining 348 patients, 
a total of 180 patients (52%), 131 IBS and 49 IBD, 
answered one or more questionnaires and were 
included in the study. Demographic characteristics 
are presented in Table 2. Twenty (11%) patients did 
not consent to extraction of data from their electronic 
patient files; therefore, only data from questionnaires 
were available. There were significant differences in 
demographic data between the two groups regarding 
IBS subtypes and IBS severity at follow-up. The IBS-D 
subtype and IBS-C subtype were more frequent in the 
IBD (P < 0.01) and IBS (P < 0.01) group, respectively, 
and the proportion of IBD patients with mild IBS at 
follow-up was significantly greater when compared to 
the IBS patients (P = 0.01). The median duration of 
follow-up from the initial dietary consultation to the 
completion of the questionnaire analysis was 16 (range: 
2-80) months overall, with 15 (range: 2-80) months 
for the IBS group, and 17 (range: 5-32) mo for the 
IBD group.
Efficacy and symptoms
One hundred and fifty patients (86%) reported either 
partial (94, 54%) or full (56, 32%) effectiveness of 
dietary treatment (Figure 2). The proportion of patients 
experiencing full effectiveness was greater in the IBD 
group than in the IBS group (42% vs 29%, P = 0.08). 
The diet showed greatest effect on bloating (82%) 
and abdominal pain (71%) (Figure 3). Furthermore, 
46 (37%) IBS patients and 21 (24%) IBD patients 
became asymptomatic while following the diet.
Disease course and stool type
Figure 4 illustrates changes in IBS disease course 
related to the LFD. After dietary treatment, the 
number of patients with a chronic continuous course 
was significantly reduced in both patient groups (IBS: 
-25%, P < 0.001; IBD: -23%, P = 0.002), while the 
mild indolent course became the predominant type 
(IBS: +37%, P < 0.001; IBD: +23%, P = 0.002). The 
mild indolent disease course following LFD intervention 
was associated with good quality of life and normal 
stool pattern (P < 0.0001). Furthermore, mild indolent 
4013 April 21, 2016|Volume 22|Issue 15|WJG|www.wjgnet.com
Table 2  Demographic data at follow-up  n  (%)
IBS IBD
Patients 131 (73) 49 (27)
Participation in eHealth studies   63 (48) 40 (82)
IBD type
   UC 32 (65)
   CD 12 (25)
   IBDU   5 (10)
   Female 107 (82) 40 (82)
   Age, median (range) 43 (18-85) 44 (19-70)
   Height, median (range)   168 (133-189)   171 (160-189)
   Weight, median (range)   65 (43-115)   75 (49-146)
   BMI, median (range) 23 (16-45) 25 (18-53)
   Smokers   15 (14)   5 (12)
IBS subtypes
   IBS-D   47 (40) 28 (67)
   IBS-C   44 (37)   6 (14)
   IBS-M   17 (14) 3 (7)
   IBS-U 10 (9)   5 (12)
IBS disease severity
   Mild 41 (32) 23 (53)
   Moderate 56 (43) 14 (33)
   Severe 32 (25)   6 (14)
   Lactose intolerance1 18 (25) 1 (6)
   Gluten intolerance2 2 (2) 1 (8)
   Food allergy3   5 (24)  5 (42)
Dietary consultations
   None 4 (4) 0 (0)
   1 30 (28) 14 (33)
   2 33 (30) 22 (53)
   3 or more 41 (38)   6 (14)
   Follow-up time, median (range) 15 (2-80) 17 (5-32)
1Diagnosed by lactose intolerance test or genetic test of lactase; 2Diagnosed 
by serologic test for immunoglobulin A tissue transaminase; 3Diagnosed 
by serologic tests for specific immunoglobulins. IBS: Irritable bowel 
syndrome; IBD: Inflammatory bowel disease; UC: Ulcerative colitis; CD: 
Crohn’s disease; IBDU: Undetermined inflammatory bowel disease; BMI: 
Body mass index; IBS-D: IBS with diarrhoea; IBS-C: IBS with constipation; 
IBS-M: Mixed IBS; IBS-U: Unsubtyped IBS.
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Figure 2  Patient-reported effectiveness of the low FODMAP diet in 
inflammatory bowel disease and irritable bowel syndrome patients at 
follow-up. Effectiveness was categorised as full, partial, or no effect. There 
were more IBD patients with full effect than IBS patients (aP = 0.08). IBD: n = 
47; IBS: n = 126. LFD: Low FODMAP diet; IBD: Inflammatory bowel disease; 
IBS: Irritable bowel syndrome.
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disease course prior to LFD was a strong predictor of 
a disease course persisting beyond the LFD (84%, P < 
0.001). Patients starting on one of the three other less 
favourable disease courses had a probability of about 
40% (range: 39%-46%) of transitioning to the mild 
indolent course after dietary treatment. The baseline 
variables showed no influence on the probability of 
changing from one of the three less favourable disease 
course types to the mild indolent course. 
There was a significant improvement of stool 
pattern in both patient groups (Figure 5). After dietary 
intervention, the proportion of patients producing 
normal stools increased, with 41% in the IBS group (P 
< 0.001) and 66% in the IBD group (P < 0.001).
adherence and satisfaction
In both patient groups, approximately one-third were 
adherent to the diet according to the FARS. Adherence 
was highest with regards to remembering to follow the 
diet and not taking breaks, and poorest when asked 
if patients followed the diet “by the book” and without 
making their own modifications (Table 2). Increased 
adherence was associated with longer duration of 
dietary treatment (P < 0.001), but otherwise no 
associations were found. Thirty-two percent of the 
IBS group and 37% of the IBD group were on the 
diet for less than three months, while 47% and 50%, 
respectively, stayed on the diet until follow-up. Fifty-
four percent used the LFD on and off depending on 
symptom severity, while the rest were continuously on 
the diet. Eighty-four percent lived on a modified LFD, 
where some foods rich in FODMAPs were reintroduced 
in varying amounts according to individual tolerance 
level, whereas the remaining patients followed the 
LFD by the book without deviations. Wheat, dairy 
products, and onions were the foods most often not 
reintroduced by patients. Weight loss occurred in 
29% of patients, while 7% gained weight during the 
dietary course. Thirty-three (26%) IBS patients and 8 
(20%) IBD patients answered that they quit the diet 
before completion of the standard dietary period. The 
most common reasons for quitting were that the diet 
was too complicated to follow (50%), too expensive 
(23%), or bland in taste (15%), and other reasons 
(53%) were co-morbidities and detrimental effect on 
functional gastrointestinal symptoms. Satisfaction 
with dietary management was seen in 83 (70%) IBS 
patients and 24 (55%) IBD patients.
Disease severity and quality of life
The overall median IBS-SSS score at follow-up was 
211 (range: 16-487). Mild IBS was associated with 
mild indolent disease course prior to LFD (P < 0.01) 
and, furthermore, was trending towards a normal stool 
type after LFD (P = 0.068). IBD patients were more 
likely to have less severe IBS at follow-up than were 
IBS patients (P < 0.05).
At follow-up, the median IBS-QoL score was 75 
(range: 37-145) for the IBS group and 63 (range: 
36-126) for the IBD group corresponding to 70 (range: 
15-98) and 79 (range: 32-99) on the transformed 
scale, respectively. For the IBD patients only, the 
median SIBDQ score was 55 (range: 23-69) and 75 
(range: 22-98) on the transformed scale. Good quality 
of life was associated with normal stool type after 
dietary therapy (P < 0.001) and duration of dietary 
course (P < 0.01). A tendency to report good quality 
of life at follow-up was observed in non-smokers and 
patients with normal stool pattern before introduction 
of LFD (P = 0.068, P = 0.060). IBD patients were 
observed to be more content with life as compared to 
IBS patients (89% vs 73%, P < 0.05).
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Figure 3  Patient-reported symptom relief for individual symptoms. Patients were able to select as many symptoms as they felt appropriate according to 
subjective symptom improvement following LFD treatment. The majority experienced relief of abdominal pain and bloating. IBD: n = 40; IBS: n =113. QoL: Quality of 
life; IBD: Inflammatory bowel disease; IBS: Irritable bowel syndrome.
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Figure 4  Changes in Copenhagen IBS disease courses after low FODMAP diet  treatment. The four different disease courses are depicted before and after 
the LFD intervention for the IBD and IBS group, separately. Above each figure, the prevalence is denoted as a percentage. The mild indolent course increased 
significantly following LFD introduction in both patient groups (P < 0.001), while the chronic continuous course and the intermittent course were less common at follow-
up. IBD: n = 43; IBS: n = 120. LFD: Low FODMAP diet; IBS: Irritable bowel syndrome; IBD: Inflammatory bowel disease.
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DISCUSSION
This study focuses on long-term outcomes of LFD 
treatment and hopes to increase global awareness of 
FODMAP restriction. It is the first survey ever to assess 
the impact of LFD on long-term IBS disease course 
and, furthermore, the longest follow-up study on IBS 
and IBD patients treated with the LFD.
Long-term IBS disease courses improved signifi-
cantly after the LFD period. Mild indolent disease 
course at baseline was a reliable predictor of remaining 
on this course after treatment. However, patients 
starting with one of the less favourable disease courses 
had a probability of about two in five of transitioning to 
a mild indolent course. This suggests that patients with 
more severe chronic courses might be able to improve 
their disease course with LFD management. Having 
said that, these data are the first on IBS disease 
course in relation to LFD and prospective cohort 
studies are needed for further investigation of whether 
or not LFD can improve disease course of IBS patients.
The prevalence of a normal stool type increased 
significantly after dietary therapy. Improvement of 
stool pattern occurred across all three groups of stool 
types, particularly in the diarrhoea group. An improved 
outcome among patients with diarrhoea was also 
found in a recent prospective study comparing LFD 
to a normal diet[13]. The enhanced efficacy of LFD in 
patients with diarrhoea could be explained by the 
osmotic nature of pooled FODMAPs in a regular diet 
which contributes to increased water output[8].
Previous studies found adherence to be of para-
mount importance to the diet’s success[12,14,16]. In this 
study, only one-third of the patients were adherent 
to the diet. High adherence was associated with 
longer duration of dietary treatment. No more than 
half of patients were still on the diet at follow-up; 
nevertheless, the majority was satisfied with the dietary 
treatment and did not quit the dietary course before 
planned. The probability of patients discontinuing 
dietary management increases with duration of dietary 
course, as motivation tends to dwindle. Gearry et 
al[14] found that use of resources (e.g., cookbooks), a 
higher educational level, and working fewer than thirty-
five hours a week were significantly related to better 
adherence.
At follow-up, most patients reported good quality 
of life and had only mild or moderate disease severity. 
Good quality of life was associated with normal stool 
type after diet and longer duration of dietary treatment, 
while mild disease severity was related to having a 
mild indolent disease course before LFD introduction. 
Two recent prospective studies by Pedersen et al[15,17] 
investigated the efficacy of LFD as compared to a 
normal diet in IBS and IBD patients and demonstrated 
a significant reduction in IBS disease severity and IBD 
disease activity, along with a significant increase in 
quality of life among IBD patients and IBS-D patients 
during the six weeks of LFD intervention.
A retrospective study is not the ideal way to 
assess efficacy of therapy and is accompanied by 
some limitations. The high rate of patients (48%) not 
replying to the invitation to join the study could have 
led to selection bias which, together with possible 
recall bias, might have resulted in type I errors. 
In the last decade it has been suggested that 
FODMAPs increase endothelial barrier permeability and, 
together with other factors, cause immune activation 
and low-grade inflammation, which could play a crucial 
role in the pathogenesis of IBS[30,31]. FODMAPs have 
been shown to influence on the colonic microbiota, 
and Halmos et al[32] recently found that diets differing 
in FODMAP content significantly affected the gut 
microflora composition and that a low FODMAP intake 
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Figure 5  Changes in stool type after low FODMAP diet  treatment. The stool types (Bristol stool chart) was categorised as normal stools, diarrhoea, constipation, 
and mixed. After the LFD, there was a significant increase in the prevalence of normal stools in both IBD and IBS patients (P < 0.001) with decreases in the remaining 
three categories of stool type, in particular the diarrhoea group (P < 0.001). IBD: n = 43; IBS: n = 121. LFD: Low FODMAP diet; IBS: Irritable bowel syndrome; IBD: 
Inflammatory bowel disease.
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was associated with reduced absolute abundance of 
bacteria. As a LFD might lead to detrimental changes 
in gut microbiota, caution should be taken when 
recommending the LFD for long-term treatment.
Although there are limitations of this study, the 
retrospective follow-up provided data supporting 
the use of LFD in both IBS and IBD with co-existing 
IBS. A majority of patients reported beneficial effects 
and satisfaction with the dietary treatment and, 
furthermore, long-term disease courses and stool 
pattern improved significantly. Long-term, prospective 
studies are needed to further investigate those 
characteristics of patients responding to the diet, 
dietary impact on IBS disease course, and the safety 
of long-term FODMAP restriction.
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Treatment of irritable bowel syndrome (IBS) is challenging due to the 
heterogeneity of the disorder, a lack of reliable outcome measures, and 
high placebo response rates. The low FODMAP diet excludes foods high in 
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monosaccharides and polyols) and has been demonstrated to be effective in 
the treatment of functional gastrointestinal symptoms. FODMAPs are poorly 
absorbed in the small intestine and are passed on to the colon, where they 
exert an osmotic effect, drawing fluid into the lumen and causing an increase 
in gas production (mainly hydrogen and methane) due to the excess delivery 
of fermentable substrates to the colonic microflora. These mechanisms can 
lead to abdominal pain, bloating, flatulence, and diarrhoea in susceptible 
subjects. In this long-term follow-up study, we evaluated the patient-reported 
outcomes among those with IBS and inflammatory bowel disease (IBD) after 
low FODMAP diet (LFD) treatment.
Research frontiers
Currently, studies of long-term efficacy of the LFD are lacking, and no one has 
yet investigated the dietary impact on IBS disease courses. The results of this 
study provide long-term patient-reported outcomes of LFD treatment and details 
on implementing the LFD.
Innovations and breakthroughs
The majority of IBS and IBD patients reported beneficial effects and satisfaction 
with the dietary treatment, although only one third was adherent. Furthermore, 
long-term IBS disease courses and stool patterns improved significantly. Eighty-
four percent of patients lived on a modified LFD, where some foods rich in 
FODMAPs were reintroduced, and 16% followed the LFD by the book without 
deviations. Wheat, dairy products, and onions were the foods most often not 
reintroduced by patients.
applications
This study suggests that the LFD is effective in the management of functional 
gastrointestinal (GI) symptoms in IBS patients and IBD patients in remission.
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low FODMAP diet in the management of patients with IBS, and those with 
functional GI symptoms in IBD. Although there are clearly limitations with such 
a retrospective study based on patient self-report questionnaires, the study 
provides some interesting long-term data.
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